Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
- Keunchil Park
- , Eng Huat Tan
- , Ken O'Byrne
- , Li Zhang
- , Michael Boyer
- , Tony Mok
- , Vera Hirsh
- , James Chih Hsin Yang
- , Ki Hyeong Lee
- , Shun Lu
- , Yuankai Shi
- , Sang We Kim
- , Janessa Laskin
- , Dong Wan Kim
- , Catherine Dubos Arvis
- , Karl Kölbeck
- , Scott A. Laurie
- , Chun Ming Tsai
- , Mehdi Shahidi
- , Miyoung Kim
- National Cancer Centre
- Queensland University of Technology
- Sun Yat-Sen University
- Chris O'Brien Lifehouse
- Chinese University of Hong Kong
- McGill University
- National Taiwan University
- Chungbuk National University
- Shanghai Jiao Tong University
- Chinese Academy of Medical Sciences
- Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
- University of Ulsan
- Provincial Health Services Authority
- Seoul National University
- Centre Georges-François Leclerc
- Karolinska Institutet
- University of Ottawa
- National Yang Ming Chiao Tung University
- Boehringer Ingelheim GmbH
- Hospital Universitario 12 de Octubre
Research output: Contribution to journal › Article › peer-review
1117
Link opens in a new tab
Scopus
citations